Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gérald Raverot"'
Autor:
Véronique Raverot, Pauline Perrin, Philippe Chanson, Emmanuel Jouanneau, Thierry Brue, Gérald Raverot
Publikováno v:
Pituitary
Pituitary, 2022, 25 (4), pp.653-657. ⟨10.1007/s11102-022-01246-8⟩
Pituitary, 2022, 25 (4), pp.653-657. ⟨10.1007/s11102-022-01246-8⟩
International audience; Purpose: Measurement of prolactin in clinical laboratories is an important component in the management of patients with pituitary adenoma. Prolactin measurement is known to be sensitive to the high-dose hook effect, in the pre
Autor:
Hélène Lasolle, Marie Teulade, Véronique Lapras, Alexandre Vasiljevic, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot
Publikováno v:
Annales d'endocrinologie. 83(1)
Dopaminergic agonists (DA) are the first-line treatment in lactotroph pituitary tumor but treatment usually needs to be life-long. After surgical transsphenoid resection, remission rates range from 60 to 90%, with low morbidity.The objective was to e
Autor:
Carine Courtillot, Marie Laure Nunes, Jérôme Bertherat, Philippe Caron, Lucie Allard, Walid Choucha, Christel Jublanc, C. Cortet, Frédérique Albarel, Philippe Chanson, Dominique Maiter, Brigitte Delemer, Emmanuelle Corruble, Sylvie Salenave, Julie Sarfati, Gérald Raverot
Publikováno v:
European journal of endocrinology. 183(2)
Context In patients treated with antipsychotics, the rare occurrence of a macroprolactinoma represents a therapeutic challenge. Objective Our aim was to evaluate the efficacy and psychiatric safety of dopamine agonists (DAs) prescribed for large macr
Autor:
Lucile Guédra, Deborah Ancelle, Emmanuel Jouanneau, Bénédicte Decoudier, Anne Fèvre, Claude-Fabien Litre, Gérald Raverot, Sara Barraud, Aurore Wolak‐Thierry, Brigitte Delemer, Françoise Borson-Chazot
Publikováno v:
Clinical Endocrinology
Clinical Endocrinology, Wiley, 2020, 92 (5), pp.421-427. ⟨10.1111/cen.14162⟩
Clinical Endocrinology, Wiley, 2020, 92 (5), pp.421-427. ⟨10.1111/cen.14162⟩
Objective Pregnancy in patients with macroprolactinomas has been associated with a higher risk of pituitary tumour growth. However, the incidence and risk factors remain unclear. We aimed to evaluate the evolution of macroprolactinomas during pregnan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9fadd26405c43992ff7d906c2dfed79
https://hal.univ-reims.fr/hal-02566667
https://hal.univ-reims.fr/hal-02566667
Publikováno v:
European journal of endocrinology. 181(2)
Recent publications suggested that pasireotide could be a good therapeutic option in some dopamine-resistant or aggressive prolactinomas. We discussed the two published cases and describe another case of poorly differentiated plurihormonal PIT-1-posi
Autor:
Alexandre Vasiljevic, Gérald Raverot, Véronique Raverot, Françoise Borson-Chazot, Hélène Lasolle, Celine Gaillard, Oana-Maria Capraru, Emmanuel Jouanneau, Jacqueline Trouillas
Publikováno v:
Annales d'Endocrinologie
Annales d'Endocrinologie, Elsevier Masson, 2019, 80, pp.216-224. ⟨10.1016/j.ando.2019.06.006⟩
Annales d'Endocrinologie, Elsevier Masson, 2019, 80, pp.216-224. ⟨10.1016/j.ando.2019.06.006⟩
TSH (thyroid-stimulating hormone)-secreting tumors are the rarest type of pituitary tumor. The objective of this study was to describe initial presentation and follow-up in patients presenting TSH-secreting tumors and to characterize the pathological
Publikováno v:
European Journal of Endocrinology. 170:R121-R132
Pituitary tumours, the most frequent intracranial tumour, are historically considered benign. However, various pieces of clinical evidence and recent advances in pathological and molecular analyses suggest the need to consider these tumours as more t
Autor:
Jacqueline Trouillas, Alexandre Vasiljevic, Laura Chinezu, Angela Borda, Patrick François, Emmanuel Jouanneau, Gérald Raverot
Publikováno v:
Human Pathology. 45:71-77
Medical treatment of endocrine pituitary tumors with somatostatin analogs depends on tumor type and somatostatin receptor (SSTR) expression. Immunohistochemical detection of these receptors using polyclonal antibodies has given conflicting results. W
Autor:
Alexa Rachwan, G. Fonteneau, José Garcia, Kristin Lucia, Véronique Raverot, Carole Auger, Jacqueline Trouillas, Emmanuel Jouanneau, Pascale Chevallier, Marily Theodoropoulou, Jérôme Honnorat, Gérald Raverot, Marie Chanal
Publikováno v:
Molecular cancer therapeutics. 15(6)
Aggressive pituitary tumors are rare but difficult to manage, as there is no effective chemotherapy to restrict their growth and cause their shrinkage. Within these tumors, growth-promoting cascades, like the PI3K/mTOR pathway, appear to be activated
Autor:
Sylvie Salenave, Anne Guiochon-Mantel, Thibaut Bahougne, Peter Kamenický, Brigitte Delemer, Agnès Linglart, Philippe Chanson, Jérôme Bouligand, Jacques Young, Gérald Raverot, Deborah Ancelle, Marc Nicolino, Pierre-François Souchon, Françoise Borson-Chazot
Publikováno v:
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, Endocrine Society, 2015, 100 (3), pp.1177-86. ⟨10.1210/jc.2014-3670⟩
Journal of Clinical Endocrinology and Metabolism, Endocrine Society, 2015, 100 (3), pp.1177-86. ⟨10.1210/jc.2014-3670⟩
International audience; BACKGROUND: Pituitary adenomas are rare in children and adolescents. The response of macroprolactinomas to dopamine agonists (DA) in this age group has been less extensively studied than in adults. OBJECTIVE: We retrospectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d74e0a8d9fa58c75039613aabce9d5
https://hal.archives-ouvertes.fr/hal-01850606
https://hal.archives-ouvertes.fr/hal-01850606